TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29220110

Group type: EXPERIMENTAL
Intervention: Strong opioids (specific types not mentioned)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Transdermal opioids
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Polypharmacological therapy
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Antidiabetic drugs, antibiotics, previous weak opioid therapy
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Anticoagulant, antidiabetic, and central nervous system drugs
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: High rating on the Karnofsky Performance Status Index
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Long-term opioids
Number of subjects: 498
Study: 27327862

Group type: EXPERIMENTAL
Intervention: High-dose bolus tirofiban
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Double-bolus eptifibatide
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Abciximab followed by a 12-hour infusion
Number of subjects: 83

Group type: COMPARATOR
Intervention: Ticagrelor or prasugrel
Number of subjects: 83

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 83
Study: 24710131

Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg/day in addition to disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 223

Group type: COMPARATOR
Intervention: DMARD therapy alone
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Prednisolone group
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (not treated with prednisolone)
Number of subjects: 223
Study: 22565381

Group type: EXPERIMENTAL
Intervention: 6-week rehabilitation group
Number of subjects: 82

Group type: COMPARATOR
Intervention: 12-week rehabilitation group
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 20415915

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 48
Study: 18607579

Group type: EXPERIMENTAL
Intervention: Low-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 0
Study: 16006422

Group type: EXPERIMENTAL
Intervention: Cancer prevention intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal-intervention control
Number of subjects: 0
Study: 14664685

Group type: EXPERIMENTAL
Intervention: Nested provider effects treated as fixed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nested provider effects treated as random
Number of subjects: 0
Study: 10947134

Group type: EXPERIMENTAL
Intervention: Eschar debridement at 48 hours after cryosurgery
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard care (no debridement)
Number of subjects: 84
Study: 8852387

Group type: EXPERIMENTAL
Intervention: Hydroxyurea 500 mg twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of hydroxyurea 500 mg twice daily and azidothymidine (AZT) 250 mg twice daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Azidothymidine (AZT) 250 mg twice daily
Number of subjects: 9
Study: 1352931

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg) + Alfentanil (15 micrograms/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pancuronium (0.1 mg/kg) + Alfentanil (15 micrograms/kg)
Number of subjects: 42
Study: 6371226

Group type: EXPERIMENTAL
Intervention: subject-alone relaxation therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: couples-relaxation therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: couples-cognitive therapy
Number of subjects: 48
Study: 31849458

Group type: EXPERIMENTAL
Intervention: Exercise plus nutrition (soy peptide supplementation)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 67
Study: 29280685

Group type: EXPERIMENTAL
Intervention: Targeted Training in Illness Management
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study: 27592690

Group type: EXPERIMENTAL
Intervention: Intermittent adductor canal block (ACB) with 15 ml of 0.5% ropivacaine every 6 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous adductor canal block (ACB) with 0.5% ropivacaine infusing at 2.5 ml/h
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intermittent ACB
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous ACB
Number of subjects: 50
Study: 25268806

Group type: EXPERIMENTAL
Intervention: β-glucan 1000 mg once daily for 7 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 22175661

Group type: EXPERIMENTAL
Intervention: Home-based expert system intervention
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Four-cluster solution
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Cluster analyses
Number of subjects: 570
Study: 19858250

Group type: EXPERIMENTAL
Intervention: Azithromycin (2 g doses given 24 h apart)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (1,500 mg or 75 mg) or chloroquine (450 mg base daily for 3 days)
Number of subjects: 60
Study: 17991116

Group type: EXPERIMENTAL
Intervention: Intravaginal slingplasty (IVS) treatment
Number of subjects: 62
Study: 16390772

Group type: EXPERIMENTAL
Intervention: 90 mg of daily genistein
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12170527

Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy for endometriosis
Number of subjects: 0
Study: 11237197

Group type: EXPERIMENTAL
Intervention: DHA-rich oil capsules containing 1.5-1.8 g DHA/d
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control oil capsules containing 97% soybean oil plus 3% fish oil
Number of subjects: 41
Study: 8874525

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moisturizer
Number of subjects: 0
Study: 1509912

Group type: EXPERIMENTAL
Intervention: Mannitol solution at 400 mOsm/kg (Group 1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mannitol solution plus allopurinol (Group 2)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall incidence
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 24-hour initial diuresis
Number of subjects: 41
Study: 6233188

Group type: EXPERIMENTAL
Intervention: Motretinide 0.1% vanishing cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Benzoyl peroxide 5% gel
Number of subjects: 30
Study: 31351241

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy-informed behavioral treatment
Number of subjects: 31
Study: 30021201

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 721

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721
Study: 28939544

Group type: EXPERIMENTAL
Intervention: Web-based aftercare program (IN@)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 253
Study: 25759972

Group type: EXPERIMENTAL
Intervention: Agatston scoring (scores of 1-100)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Agatston scoring (scores of 101-1000)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Agatston scoring (scores greater than 1000)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Summed segmented vessel-specific scores (scores of 1-5)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Summed segmented vessel-specific scores (scores of 6-11)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Summed segmented vessel-specific scores (scores of 12-30)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Overall visual assessment (mild)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Overall visual assessment (moderate)
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Overall visual assessment (heavy)
Number of subjects: 1575
Study: 23845200

Group type: EXPERIMENTAL
Intervention: TrP therapy (manual pressure applied to taut bands and passive stretching)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simulated TrP therapy (no additional pressure, longitudinal stroking but no additional stretching)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TrP therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simulated TrP therapy
Number of subjects: 20
Study: 21933376

Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment (IST) of malaria
Number of subjects: 0
Study: 18953260

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 16403592

Group type: EXPERIMENTAL
Intervention: Fructose supplementation (7.5 g) tri‐daily after each main meal
Number of subjects: 26

Group type: COMPARATOR
Intervention: Maltodextrin supplementation (7.5 g) tri‐daily after each main meal
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fructose supplementation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Maltodextrin supplementation
Number of subjects: 26
Study: 14665349

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Contact laser prostatectomy
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Electrovaporization
Number of subjects: 141

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 141
Study: 11188390

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with biofeedback
Number of subjects: 0
Study: 9377069

Group type: EXPERIMENTAL
Intervention: Large-volume leukapheresis
Number of subjects: 17
Study: 8242506

Group type: EXPERIMENTAL
Intervention: MMR vaccine administered at 13 months
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: MMR vaccine administered at 15 months
Number of subjects: 376

Group type: COMPARATOR
Intervention: MMR vaccine (both groups)
Number of subjects: 376
Study: 3011174

Group type: EXPERIMENTAL
Intervention: Weighted traction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated traction
Number of subjects: 0
Study: 30116551

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 0
Study: 27363988

Group type: EXPERIMENTAL
Intervention: Aerobic dance programme (60 minutes, 3 times a week for 3 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Colouring and handwriting activities (control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aerobic dance programme
Number of subjects: 36
Study: 25049325

Group type: EXPERIMENTAL
Intervention: Counseling with results of psychosocial questionnaire provided to counselors before the session
Number of subjects: 246
Study: 23363776

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinyl palmitate per day for 4 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (one capsule per day for 4 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 20829329

Group type: EXPERIMENTAL
Intervention: T/FAC (weekly paclitaxel × 12 followed by FAC × 4)
Number of subjects: 273

Group type: COMPARATOR
Intervention: FAC (FAC × 6)
Number of subjects: 273
Study: 18027040

Group type: EXPERIMENTAL
Intervention: Graduated balloon dilation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bougie-over-a-guidewire dilation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Handsewn anastomoses
Number of subjects: 42

Group type: COMPARATOR
Intervention: Combined stapled and handsewn anastomoses
Number of subjects: 42
Study: 15930095

Group type: EXPERIMENTAL
Intervention: Crit-Line monitoring
Number of subjects: 443

Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 443
Study: 12502991

Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia followed by PCEA (PA + PCEA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCEA
Number of subjects: 0
Study: 11220522

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg once daily
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 8695089

Group type: EXPERIMENTAL
Intervention: Pressure support (PS) titrated to produce a tidal volume (VT) of 8 ml/kg body weight
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pressure support (PS) at 5 cmH2O
Number of subjects: 20
Study: 7949749

Group type: EXPERIMENTAL
Intervention: Cyclic oestrogen/progestogen therapy (group 1, n = 20)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Daily oral calcium dose of 2 g (group 2, n = 17)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Intermittent cyclic etidronate therapy (group 3, n = 19)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ADFR treatment with triiodothyronine and etidronate (group 4, n = 18)
Number of subjects: 74
Study: 3358644

Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose 5.7 mg)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo (mean daily dose 7.5 capsules)
Number of subjects: 525
Study: 30390894

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support (126 kJ/kg and 1.5-2.0 g protein/kg) during hospitalization
Number of subjects: 119

Group type: COMPARATOR
Intervention: Routine feeding (control group)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 119
Study: 28166812

Group type: EXPERIMENTAL
Intervention: HIFU-assisted liver resection (HIFU-AR)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard crushing technique (Control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: HIFU-AR
Number of subjects: 42
Study: 26414380

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no CPAP)
Number of subjects: 91
Study: 22889336

Group type: EXPERIMENTAL
Intervention: Organizational Skills Training (OST)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: PATHKO
Number of subjects: 158

Group type: COMPARATOR
Intervention: Wait-list Control (WL)
Number of subjects: 158
Study: 21124326

Group type: EXPERIMENTAL
Intervention: Olmesartan plus a calcium channel blocker (CCB)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Olmesartan plus a thiazide diuretic
Number of subjects: 65
Study: 19145003

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily
Number of subjects: 8600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8600
Study: 17925548

Group type: EXPERIMENTAL
Intervention: Carboplatin and taxane regimens
Number of subjects: 914

Group type: COMPARATOR
Intervention: Previously reported genotype associations
Number of subjects: 914
Study: 15310999

Group type: EXPERIMENTAL
Intervention: Immediate endocrine treatment (luteinizing hormone‐releasing hormone agonist and 1 month of antiandrogen treatment or surgical castration)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Delayed endocrine treatment
Number of subjects: 302
Study: 11510901

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave application (ESWA)
Number of subjects: 42
Study: 9574876

Group type: EXPERIMENTAL
Intervention: Multi-Test
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ALK lancet
Number of subjects: 28
Study: 8534760

Group type: EXPERIMENTAL
Intervention: Aerosol amphotericin B inhalations (10 mg twice daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No aerosol amphotericin B prophylaxis
Number of subjects: 115
Study: 2143046

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg two or three times daily for 3 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 318609

Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sulfisoxazole
Number of subjects: 100
Study: 31232992

Group type: EXPERIMENTAL
Intervention: Extraoral approach for BTX‐A injection into the lateral pterygoid muscle (20 IU BTX‐A)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intraoral approach for BTX‐A injection into the lateral pterygoid muscle (20 IU BTX‐A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both approaches (Extraoral and Intraoral)
Number of subjects: 14
Study: 28363363

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 0.25 mg/kg/dose every 6 hours for 48 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo every 6 hours for 48 hours
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) for simple effusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for simple effusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) for complicated effusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for complicated effusion
Number of subjects: 60
Study: 26198855

Group type: EXPERIMENTAL
Intervention: CARe methodology training from a specialized institute
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 23972540

Group type: EXPERIMENTAL
Intervention: Healing Touch (HT) and Body Talk Cortices (BTC) for 6 months, with weekly HT sessions and daily BTC technique.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group with no additional interventions.
Number of subjects: 22
Study: 21912341

Group type: EXPERIMENTAL
Intervention: Gradual-elastic compression stockings (GCSs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no GCSs)
Number of subjects: 16
Study: 18326222

Group type: EXPERIMENTAL
Intervention: Nizhne-Ivkinskaya 2K mineral water for 21 days
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 134
Study: 16359741

Group type: EXPERIMENTAL
Intervention: Folic acid 5mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15011964

Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 27
Study: 11117090

Group type: COMPARATOR
Intervention: pre‐eclampsia/eclampsia syndrome
Number of subjects: 66

Group type: COMPARATOR
Intervention: eclamptic patients
Number of subjects: 66

Group type: COMPARATOR
Intervention: pre‐eclamptic patients
Number of subjects: 66

Group type: COMPARATOR
Intervention: isolated HELLP syndrome
Number of subjects: 66
Study: 2187585

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (8 mg orally three times a day)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 7033008

Group type: EXPERIMENTAL
Intervention: Des-phe insulin (regular and semilinte preparations)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Des-phe insulin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unmodified insulin
Number of subjects: 24
Study: 31951260

Group type: EXPERIMENTAL
Intervention: Evidence‐Based Amputee Rehabilitation program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wait‐list control group
Number of subjects: 20
Study: 30426602

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical hysterectomy (RARH)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Conventional laparoscopic radical hysterectomy (LRH)
Number of subjects: 121
Study: 28954583

Group type: EXPERIMENTAL
Intervention: 200 microTesla MF (3 minutes duration) at three frequencies (10, 14 and 18 Hz)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham operation
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: ELF-MF exposure
Number of subjects: 65
Study: 27519620

Group type: EXPERIMENTAL
Intervention: Booster vaccination of SA3Ag
Number of subjects: 345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: High-dose level SA3Ag
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Initial vaccination of SA3Ag
Number of subjects: 345
Study: 24969735

Group type: EXPERIMENTAL
Intervention: Weed-Check (motivational interviewing intervention)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 119
Study: 22336473

Group type: EXPERIMENTAL
Intervention: Cilostazol (200mg/day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Aspirin (100mg/day)
Number of subjects: 106
Study: 20511269

Group type: EXPERIMENTAL
Intervention: Preferred work accommodations (fewer work hours, working from home, slower work pace, more autonomy in planning work tasks)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Psychosocial problems (work-home interference, lack of acceptance of chronic disease)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Managing psychosocial problems
Number of subjects: 122
Study: 17685844

Group type: EXPERIMENTAL
Intervention: ACIDFORM gel with a diaphragm
Number of subjects: 120
Study: 16015060

Group type: EXPERIMENTAL
Intervention: Endovascular therapies including protection and thromboaspiration devices, new atherectomy devices, and cryoplasty.
Number of subjects: 0
Study: 12037225

Group type: EXPERIMENTAL
Intervention: Induced sputum from asthmatic patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Induced sputum from normal control subjects
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation with FEV(1) % predicted
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation with bronchial hyperreactivity to methacholine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation with eosinophilic airway inflammation (% eosinophils)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation with eosinophil cationic protein
Number of subjects: 25
Study: 10543269

Group type: EXPERIMENTAL
Intervention: NPSV in sitting posture
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sitting NPSV
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: VAS (Visual Analogue Scale)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Changing posture
Number of subjects: 12
Study: 7783062

Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg qid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40